ROCKET PHARMACEUTICALS, INC.

Investments consist of U.S. Treasury Securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to ASC 320, Investments-Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. The Company estimates expected credit losses for investments when unrealized losses exist. Unrealized losses that are credit related are recognized in the Company’s Consolidated Statement of Operations and unrealized losses that are not credit related are recognized in accumulated other comprehensive income (loss). For the three and nine months ended September 30, 2025 and 2024, there wereno unrealized losses that were credit related. For thethree and nine months ended September 30, 2025, there were net unrealized gain on investments of$0.1 million and net unrealized loss on investment of$0.1 million, respectively. For the three and nine months ended September 30, 2024, there were net unrealized gain on investments of$0.4 million and net unrealized loss on investment of$0.1 million, respectively.